# Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

> **NCT02585934** · PHASE3 · COMPLETED · sponsor: **Axovant Sciences Ltd.** · enrollment: 1315 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** RVT-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02585934
- **Lead sponsor:** Axovant Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 1315 (ACTUAL)
- **Last updated:** 2018-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585934, "Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02585934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*